BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35741779)

  • 21. Identification of potential targets of triptolide in regulating the tumor microenvironment of stomach adenocarcinoma patients using bioinformatics.
    Qiu H; Zhang X; Yu H; Gao R; Shi J; Shen T
    Bioengineered; 2021 Dec; 12(1):4304-4319. PubMed ID: 34348580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
    Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
    Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
    Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
    Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
    Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
    Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer.
    Zhang D; He W; Wu C; Tan Y; He Y; Xu B; Chen L; Li Q; Jiang J
    Front Immunol; 2019; 10():71. PubMed ID: 30761139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of L1 methylation and tumor-infiltrating lymphocytes as prognostic marker in advanced gastric cancer.
    Kim Y; Rhee YY; Wen X; Cho NY; Bae JM; Kim WH; Kang GH
    Gastric Cancer; 2020 May; 23(3):464-472. PubMed ID: 31691036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylation statuses of NCOR2, PARK2, and ZSCAN12 signify densities of tumor-infiltrating lymphocytes in gastric carcinoma.
    Wen X; Jin HY; Li M; Kim Y; Cho NY; Kwak Y; Bae JM; Lee HS; Kang GH
    Sci Rep; 2022 Jan; 12(1):862. PubMed ID: 35039565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
    Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
    Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
    [No Abstract]   [Full Text] [Related]  

  • 30. Fatty Acid Oxidation Controls CD8
    Lin R; Zhang H; Yuan Y; He Q; Zhou J; Li S; Sun Y; Li DY; Qiu HB; Wang W; Zhuang Z; Chen B; Huang Y; Liu C; Wang Y; Cai S; Ke Z; He W
    Cancer Immunol Res; 2020 Apr; 8(4):479-492. PubMed ID: 32075801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
    Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
    Front Immunol; 2022; 13():854785. PubMed ID: 35392086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer.
    Dai C; Geng R; Wang C; Wong A; Qing M; Hu J; Sun Y; Lo AW; Li J
    Mol Oncol; 2016 Dec; 10(10):1551-1558. PubMed ID: 27720576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
    Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
    Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TUMOR INFILTRATING LYMPHOCYTES PECULIARITIES IN DIFFERENT HISTOPATHOLOGICAL AND MOLECULAR SUBTYPES OF GASTRIC CARCINOMA.
    Museridze N; Tutisani A; Chabradze G; Beridze N; Muzashvili T
    Georgian Med News; 2021 Jun; (315):165-168. PubMed ID: 34365444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression.
    Whiteside TL
    Exp Suppl; 2022; 113():89-106. PubMed ID: 35165861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
    Zhang S; Lv M; Cheng Y; Wang S; Li C; Qu X
    BMC Cancer; 2021 Dec; 21(1):1324. PubMed ID: 34893046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists.
    Lang-Schwarz C; Melcher B; Hartmann A; Bertz S; Dregelies T; Lang-Schwarz K; Vieth M; Sterlacci W
    Int J Colorectal Dis; 2021 Nov; 36(11):2497-2510. PubMed ID: 34170390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 40. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.